NCT00591994

Brief Summary

Tinnitus is defined as the perception of sound in the absence of a external source. About 15 % of the population is believed to experience tinnitus and for about 20 % of them it may become a very serious problem. Total comprehension of tinnitus pathophysiology has not yet been achieved, but modern theories focus in brain hyperactivity following inner ear damage, with involvement of various neurotransmitters. Piribedil,a dopamin agonist, has been used to treat tinnitus, focusing in dopamine release, which is inhibitory. Electrophysiological methods,like acoustic otoemissions and electrocochleography may reveal the changes in peripherical and central auditory pathways and help to choose the specific patients who could benefit from piribedil treatment.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2006

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2007

Completed
25 days until next milestone

First Submitted

Initial submission to the registry

December 26, 2007

Completed
16 days until next milestone

First Posted

Study publicly available on registry

January 11, 2008

Completed
Last Updated

March 7, 2008

Status Verified

December 1, 2007

Enrollment Period

1.1 years

First QC Date

December 26, 2007

Last Update Submit

March 6, 2008

Conditions

Keywords

tinnituspiribedilacoustic otoemissionsECoG

Outcome Measures

Primary Outcomes (1)

  • THI - Tinnitus Handicap Inventory

    Months 3 and 6

Secondary Outcomes (1)

  • VAS - Visual Analog Scale

    Months 3 and 6

Interventions

50 mg once a day, after lunch 3 month therapy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • tinnitus for more than 6 months
  • THI \> 38
  • no central acting drugs in the last 6 months
  • tympanogram type A-n

You may not qualify if:

  • vascular and muscular tinnitus
  • concomitant TMJ disorders
  • abnormal otoscopy
  • mixed and conductive hearing losses

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

OTOSUL,Otorrinolaringologia Sul-Fluminense

Volta Redonda, Rio de Janeiro, 27255-650, Brazil

Location

Related Publications (1)

  • de Azevedo AA, Langguth B, de Oliveira PM, Rodrigues Figueiredo R. Tinnitus treatment with piribedil guided by electrocochleography and acoustic otoemissions. Otol Neurotol. 2009 Aug;30(5):676-80. doi: 10.1097/MAO.0b013e3181ab8fd5.

MeSH Terms

Conditions

Tinnitus

Interventions

Piribedil

Condition Hierarchy (Ancestors)

Hearing DisordersEar DiseasesOtorhinolaryngologic DiseasesSensation DisordersNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PiperazinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Ricardo R Figueiredo, M.D.,M.Sc

    Faculdade de Medicina de Valença

    STUDY CHAIR
  • Andréia A Azevedo, M.D.

    Otosul -Otorrinolaringologia Sul-Fluminense

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 26, 2007

First Posted

January 11, 2008

Study Start

November 1, 2006

Primary Completion

December 1, 2007

Last Updated

March 7, 2008

Record last verified: 2007-12

Locations